These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25872123)

  • 1. Gastrointestinal toxicities from targeted therapies: measurement, duration and impact.
    Bossi P; Lucchesi M; Antonuzzo A
    Curr Opin Support Palliat Care; 2015 Jun; 9(2):163-7. PubMed ID: 25872123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
    Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment and management of gastrointestinal toxicities and lab abnormalities related to targeted therapy.
    Fischer-Cartlidge EA
    Semin Oncol Nurs; 2014 Aug; 30(3):183-9. PubMed ID: 25085030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Management of adverse effects of targeted therapy toxicities in oncology].
    Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
    Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal models of mucositis: critical tools for advancing pathobiological understanding and identifying therapeutic targets.
    Wardill HR; Tissing WJE; Kissow H; Stringer AM
    Curr Opin Support Palliat Care; 2019 Jun; 13(2):119-133. PubMed ID: 30925531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors.
    Pilotte AP; Hohos MB; Polson KM; Huftalen TM; Treister N
    Clin J Oncol Nurs; 2011 Oct; 15(5):E83-9. PubMed ID: 21951751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
    Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
    Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making the Grade: The Impact of Low-Grade Toxicities on Patient Preference for Treatment With Novel Agents.
    Castellanos EH; Chen SC; Drexler H; Horn L
    J Natl Compr Canc Netw; 2015 Dec; 13(12):1490-5. PubMed ID: 26656518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regimen-related gastrointestinal toxicities in cancer patients.
    Sonis ST
    Curr Opin Support Palliat Care; 2010 Mar; 4(1):26-30. PubMed ID: 20040879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice.
    Peterson DE; Keefe DM; Hutchins RD; Schubert MM
    Support Care Cancer; 2006 Jun; 14(6):499-504. PubMed ID: 16775646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
    Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events of targeted therapies.
    Klastersky JA
    Curr Opin Oncol; 2014 Jul; 26(4):395-402. PubMed ID: 24825019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Side effects of targeted therapies: rash.
    Eaby-Sandy B; Lynch K
    Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.
    Sonis S; Treister N; Chawla S; Demetri G; Haluska F
    Cancer; 2010 Jan; 116(1):210-5. PubMed ID: 19862817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
    Kirkali Z
    BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there room for improvement in adverse event reporting in the era of targeted therapies?
    Edgerly M; Fojo T
    J Natl Cancer Inst; 2008 Feb; 100(4):240-2. PubMed ID: 18270340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal toxicity of chemotherapeutic agents.
    Mitchell EP
    Semin Oncol; 2006 Feb; 33(1):106-20. PubMed ID: 16473649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy.
    Villa A; Kuten-Shorrer M
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.